Skip to main content

Advertisement

SpringerLink
Log in

Infliximab has no apparent effect in the inner ear hearing function of patients with rheumatoid arthritis and ankylosing spondylitis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Animal studies suggest that tumor necrosis factor (TNF) alpha blockers may pass to the inner ear in adequate concentration. In this prospective study, we aimed to evaluate the effect of infliximab on the inner ear hearing function in patients with ankylosing spondylitis (AS) and rheumatoid arthritis (RA). The patients with high disease activity, who were planned to begin infliximab for therapy by physical medicine and rehabilitation department, were referred to ear–nose–throat clinic for consultation. After physical and otoscopic examination, audiological tests were performed. Air conduction thresholds between 250 and 8,000 Hz, bone conduction thresholds between 500 and 4,000 Hz, pure tone average, speech discrimination scores, distortion product otoacoustic emission (DPOAE) were used to evaluate the hearing function. The tests were repeated 2 and 6 months after the initiation of the drug “infliximab.” A total of 44 ears of 22 patients (17 males and 5 females) were evaluated. Fifteen patients had a diagnosis of AS, and seven patients had RA. After initiation of infliximab therapy, statistically significant improvement was observed in disease activity scores [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for AS, Disease Activity Score 28 (DAS-28) for RA] after 2 and 6 months (p < 0.05). We did not find any statistically significant difference between the air conduction thresholds, bone conduction thresholds, pure tone average, speech discrimination scores, and measurements of DPOAE before the initiation of treatment and after 2 and 6 months (p > 0.05). Any problem about the balance, vertigo, or dizziness was not reported from the patients during the treatment period. As a result, our study showed that there was no notable change or deterioration in the hearing function of the patients with AS and RA who were treated with infliximab. Further studies with higher number of patients with AS and RA and also with different TNF alpha inhibitors are needed to make more valid conclusion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Jain A, Singh JA (2013) Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy 5(3):265–299

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  2. Savastano M, Marioni G, Giacomelli L, Ramonda R, Ferraro SM, Punzi L (2010) Sensorineural hearing loss in ankylosing spondylitis treated with TNF blockers. B-ENT 6:183–188

    PubMed  CAS  Google Scholar 

  3. McCabe BF (1979) Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol 113:526–530

    Google Scholar 

  4. Touma Z, Nawwar R, Hadi U, Hourani M, Arayssi T (2007) The use of TNF blockers in Cogan’s syndrome. Rheumatol Int 27:995–996

    Article  PubMed  CAS  Google Scholar 

  5. Fricker M, Baumann A, Wermelinger F, Villiger PM, Helbling A (2007) A novel therapeutic option in Cogan diseases? TNF-alpha blockers. Rheumatol Int 27:493–495

    Article  PubMed  CAS  Google Scholar 

  6. Lee DH, Yeo SW, Chang KH, Park SY, Oh JH, Seo JH (2008) Effect of infliximab on experimentally induced otitis media in rats. Ann Otol Rhinol Laryngol 117(6):470–476

    PubMed  Google Scholar 

  7. Lamm K, Lamm H, Arnold W (1998) Effect of hyperbaric oxygen therapy in comparison to conventional or placebo therapy or no treatment in idiopathic sudden hearing loss, acoustic trauma, noise-induced hearing loss and tinnitus. A literature survey. Adv Otorhinolaryngol 54:86–99

    PubMed  CAS  Google Scholar 

  8. Smollen JS, Infliximab EP (2011) 12 years of experience. Arthritis Res Ther 13(Suppl 1):S2

    Google Scholar 

  9. Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916

    Article  PubMed  CAS  Google Scholar 

  10. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105–1110

    Article  PubMed  CAS  Google Scholar 

  11. Conaghan PG, Quinn MA, O’Connor P, Wakefield RJ, Karim Z, Emery P (2002) Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission? Arthritis Rheum 46:1971–1972

    Article  PubMed  Google Scholar 

  12. Braun J, Landewé R, Hermann K-G, Han J, Yan S, Williamson P, van der Heijde D (2006) ASSERT Study Group: major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo controlled magnetic resonance imaging study. Arthritis Rheum 54:1646–1652

    Article  PubMed  CAS  Google Scholar 

  13. Antoni C, Braun J (2002) Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 20(Suppl 28):S152–S157

    PubMed  CAS  Google Scholar 

  14. Axelsson A (1968) The vascular anatomy of the cochlea in the guinea pig and in man. Acta Otolaryngol Suppl 243:3

    Google Scholar 

  15. Nakashima T, Naganawa S, Some M et al (2003) Disorders of cochlear blood flow. Brain Res Rev 43:17–28

    Article  PubMed  Google Scholar 

  16. Scherer EQ, Yang J, Canis M et al (2010) Tumor necrosis factor alpha enhances microvascular tone and reduces blood flow in the cochlea via enhanced sphingosine-1-phosphate signaling. Stroke 41:2618–2624

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Lobo D, Trinidad A, Garcia-Berrocal JR, Verdaguer JM, Ramirez-Camacho R (2006) TNF-alpha blockers do not improve the hearing recovery obtained with glucocorticoid in an autoimmune experimental labyrinthitis. Eur Arch Otorhinolaryngol 263:622–626

    Article  PubMed  Google Scholar 

  18. Job A, Nottet JB (2002) DPOAEs in young normal-hearing subjects with histories of otitis media: evidence of sub-clinical impairments. Hear Res 167(1–2):28–32

    Article  PubMed  Google Scholar 

  19. Okur E, Kilinc M, Yildirim I, Kilic MA, Tolun FI (2007) Effect of N-acetylcysteine on carboplatin-induced ototoxicity and nitric oxide levels in a rat model. Laryngoscope 117(12):2183–2186

    Article  PubMed  CAS  Google Scholar 

  20. Ihler F, Sharaf K, Bertlich M, Strieth S, Reichel CA, Berghaus A, Canis M (2013) Etanercept prevents decrease of cochlear blood flow dose-dependently caused by tumor necrosis factor alpha. Ann Otol Rhinol Laryngol 122(7):468–473

    PubMed  Google Scholar 

  21. Heywood RL, Hadavi S, Donnelly S, Patel N (2013) Infliximab for autoimmune inner ear disease: case report and literature review. J Laryngol Otol 127(11):1145–1147

    Article  PubMed  CAS  Google Scholar 

  22. Lobo D, García-Berrocal JR, Trinidad A, Verdaguer JM, Ramírez-Camachob R (2013) Review of the biological agents used for immune-mediated inner ear disease. Acta Otorrinolaringol Esp 64(3):223–229

    Article  PubMed  Google Scholar 

  23. Belinchon A, Perez-Garrigues H, Tenias JM (2012) Evolution of symptoms in Ménière’s disease. Audiol Neuro Otol 17(2):126–132

    Article  Google Scholar 

  24. Rotstein C, Mandell L (2004) Clinical aminoglycoside ototoxicity. In: Roland PS, Rutka JA (eds) Ototoxicity. BC Decker Inc, Canada, pp 82–93

    Google Scholar 

  25. Schmidt CM, Knief A, Lagosch AK, Deuster D, Am Zehnhoff-Dinnesen A (2008) Left-right asymmetry in hearing loss following cisplatin therapy in children-the left ear is slightly but significantly more affected. Ear Hear 29(6):830–837

    Article  PubMed  Google Scholar 

Download references

Funding

None

Conflict of interest

The authors have no conflict of interest to disclose.

Author information

Authors and Affiliations

  1. Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Afyon Kocatepe University, 03200, Afyonkarahisar, Turkey

    H. Toktas, U. Dundar & A. Dikici

  2. Faculty of Medicine, Department of Otorhinolaryngology, Afyon Kocatepe University, Afyonkarahisar, Turkey

    E. Okur & O. K. Kahveci

Authors
  1. H. Toktas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Okur
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U. Dundar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Dikici
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O. K. Kahveci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U. Dundar.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toktas, H., Okur, E., Dundar, U. et al. Infliximab has no apparent effect in the inner ear hearing function of patients with rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol 33, 1481–1487 (2014). https://doi.org/10.1007/s10067-014-2625-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-014-2625-z

Keywords

Search

Navigation